Medela Potentia (MDLA) Fundamentals 2026 — P/E 7.1x, Revenue Analysis | SniperIQ
Medela Potentia (MDLA) is a ID-listed Healthcare company in Medical - Distribution with a market capitalization of Rp2.94T, trading at Rp210.00 on the JKT. This SniperIQ fundamentals page covers Medela Potentia's valuation (P/E 7.1x, P/B 0.9x), profitability (net margin 2.7%), revenue (Rp14.89T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Medela Potentia's market cap?
Medela Potentia (MDLA) has a market capitalization of approximately Rp2.94T, trading at Rp210.00 on the JKT. Market cap moves with the live share price.
What is Medela Potentia's P/E ratio?
Medela Potentia's trailing twelve-month P/E ratio is 7.1x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Medela Potentia?
Medela Potentia runs a net profit margin of 2.7%, a gross margin of 9.4%, and an operating margin of 3.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Medela Potentia generate?
Medela Potentia reported revenue of Rp14.89T for fiscal year 2025, with net income of Rp392.3B and earnings per share (EPS) of 27.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Medela Potentia pay a dividend?
Medela Potentia offers a trailing dividend yield of about 10.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Medela Potentia financially healthy?
Medela Potentia carries a debt-to-equity ratio of 0.02x and a current ratio of 1.75x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Medela Potentia a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medela Potentia (MDLA) the key facts are: market cap Rp2.94T, P/E 7.1x, revenue Rp14.89T, 52-week range 175-318. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Medela Potentia's full fundamentals live
Get Medela Potentia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.